Professional Documents
Culture Documents
Research Is To See What Everyone Has Seen and To Think What Nobody Has Thought. "Albert Szent-Gyoergyi, Nobel Prize 1937
Research Is To See What Everyone Has Seen and To Think What Nobody Has Thought. "Albert Szent-Gyoergyi, Nobel Prize 1937
Lean genes allow you to eat without gaining weight Nature did it, ObeTherapy can reproduce it.
The Company
Created by Dr Itzik HAROSH in January 2000 Strong team of 6 researchers 5 patents giving a full scientific protection One industry contract with Zambon Group SpA (Milan, Italy) Several biotech collaborations One academic collaboration with INRA (France) Member of the Genopole at Evry, France
Core Team
Itzik HAROSH, PhD, Chairman and Chief Scientist
Officer (CSO)
Georges GAUDRIAULT, PhD, Scientific Director Sandrine BRAUD, PhD, Project Leader Vladimir CHARRON, Engineer David SENAC, Engineer Christelle MOUGIN, Laboratory Manager
Advisory board
Prof. M. Radman, Hpital Necker, Paris, France; specialist in genetics and evolution;
member of the "Acadmie des Sciences de l'Institut de France".
Prof. T. Baasov, Chemistry Faculty Technion, Haifa, Israel; specialist in medicinal chemistry
and chemical synthesis.
Prof. B. Peault, McGowan Institute for Regenerative Medicine, Pittsburgh, USA; specialist in
cellular models and biotechnology, pioneer of Systemix.
Dr Y. Champey, former Senior Vice President and Executive Medical Director at RhnePoulenc Rorer.
Prof. M. Rubinstein, Weizmann Institute, Israel; Geneticist, Expert in the obesity field. Prof. D. Ricquier, PhD, Director of CEREMOD/CNRS Unit 9078, Hpital Necker-Enfants
Malades, France, Expert in the obesity field in which he is a major contributor; member of the "Acadmie des Sciences de l'Institut de France".
5
Mission
With a completely innovative strategy, Obetherapy aims to develop medication for obesity. By looking for lean genes or expenditure genes in lean phenotype
What is Obesity ? Obesity = imbalance between food intake and energy expenditure
Energy expenditure
(metabolism& physical activity)
Food intake
Absorption
Type II diabete
Obesity
Metabolism
Carbohydrates Carbohydrate Proteins Lipids Lipids
Acetyl-CoA Acetyl-CoA
ATP
9
7 41 90 322 460
http://obesitygene.pbrc.edu
10
Targets for obesity treatment currently in research and development Energy Appetit NPY Orexin PTP-1B AGRP MG Axokine CNTF Canabinoid
(Rimonabant)
Satiety OB DB CCK POMC MCH Tubby CART Agouty FAT GLP-1 MC4R MC4R PYY (3-36)
homeostasis
Fat metabolism PPAR- SREBP1 C/EBPs FATPs Fat Absorption PL (Orlistat) MTP
-Adrenergic R -Adrenergic R
ACC-2 Adiponectin
(Famoxin)
PTP1B S6K1
11
12
13
Is this an advantage?
14
When food supply increased the thrifty genotype On the other hand, individuals with low efficiency
for food absorption and energy metabolism became rare.
Obetherapy strategy
Using the Lean Genes or Expenditure genes as Potential Targets for the Treatment of Obesity and Type II diabetes
16
Improved Leads
Lead Optimization
Medicinal Chemistry
Target n1 Target n2
17
18
Metabolism
VLDL/LDL Bile
Chylomicrons
Adipocytes
HDL
Intestine
Storage
Absorption
Lipids are transported by chylomicrons (from intestine to liver) and by VLDL/LDL/HDL (from liver to target tissue). OBETHERAPY CAN STOP TOTALLY OR PARTIALLY THE PROCESS. 19
Transgenic (F1)
Control (F1)
20
Status on target n 1 Development collaboration signed in 2004 with Zambon Group SpA. Zambon Group SpA was founded in Vicenza in 1906. It operates in Europe, South America and Asia. It employs 2,300 employees in 16 countries and has consolidated sales in the region around 500m. Some scientific data: High throughput screening using ObeTherapys proprietary technology was conducted late 2004. HIT identification milestone was reached in April 2005. Lead identification milestone was reached in October 2005. Next milestone will characterize the Candidate Drug to enter preclinical mid 2007.
21
SOME FACTS
5 PATENTS: First ObeTherapys target on lipids (issued EU and US)
Second ObeTherapys target on proteins (PCT application) Biochemical in vitro assay: (issued F & US) List of hit compounds (PCT) Cellular HTS (PCT)
22
Investment opportunities
ObeTherapy is looking to raise 3 million euros for the next 2 years.
(i) Coinvest with Zambon and share risk on the development of the first program. (ii) Bring the second program to preclinical stage.
23
Lean genes allow you to eat without gaining weight... Nature did it, ObeTherapy can reproduce it.